Kezar Life Sciences, Inc. (NASDAQ:KZR) Forecasted to Post Q1 2023 Earnings of ($0.26) Per Share

Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Analysts at William Blair issued their Q1 2023 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a research report issued to clients and investors on Wednesday, March 15th. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.26) per share for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2023 earnings at ($0.25) EPS, Q3 2023 earnings at ($0.25) EPS, Q4 2023 earnings at ($0.28) EPS, FY2023 earnings at ($1.04) EPS, FY2024 earnings at ($0.93) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.87) EPS.

KZR has been the topic of a number of other research reports. Wells Fargo & Company lowered their target price on Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, January 3rd. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Kezar Life Sciences in a research note on Thursday.

Kezar Life Sciences Trading Down 1.6 %

Kezar Life Sciences stock opened at $3.76 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 25.98 and a quick ratio of 31.15. Kezar Life Sciences has a one year low of $3.55 and a one year high of $18.55. The stock has a market capitalization of $266.22 million, a PE ratio of -3.72 and a beta of 0.25. The business’s fifty day moving average is $6.21 and its 200 day moving average is $7.26.

Insider Buying and Selling

In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 40,000 shares of the firm’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $6.88, for a total transaction of $275,200.00. Following the transaction, the insider now owns 5,447,993 shares of the company’s stock, valued at approximately $37,482,191.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 248,276 shares of company stock valued at $1,708,683 in the last 90 days. Company insiders own 7.80% of the company’s stock.

Institutional Trading of Kezar Life Sciences

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in shares of Kezar Life Sciences by 264.2% during the 1st quarter. JPMorgan Chase & Co. now owns 63,788 shares of the company’s stock valued at $1,060,000 after acquiring an additional 46,275 shares during the period. MetLife Investment Management LLC increased its holdings in Kezar Life Sciences by 55.7% in the 1st quarter. MetLife Investment Management LLC now owns 20,139 shares of the company’s stock valued at $335,000 after purchasing an additional 7,203 shares during the last quarter. Rhumbline Advisers increased its holdings in Kezar Life Sciences by 15.0% in the 1st quarter. Rhumbline Advisers now owns 46,517 shares of the company’s stock valued at $773,000 after purchasing an additional 6,051 shares during the last quarter. BlackRock Inc. increased its holdings in Kezar Life Sciences by 7.8% in the 1st quarter. BlackRock Inc. now owns 2,897,074 shares of the company’s stock valued at $48,150,000 after purchasing an additional 210,050 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Kezar Life Sciences by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 277,928 shares of the company’s stock worth $4,619,000 after acquiring an additional 2,130 shares in the last quarter. 84.03% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.